Diffuse Large B-Cell Lymphoma Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 - 2025

  • Single User License $3500

Diffuse Large B-Cell Lymphoma Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 - 2025

Status : September, 2020 | Healthcare IT | PPT format

Report Digest


Diffuse Large B-Cell Lymphoma Market - Snapshot

Diffuse large B-Cell Lymphoma is seeing a rise in its incidence worldwide. As per U.K. Lyphoma Association, Britain lone sees about 4800 cases of this every year. The biggest challenge behind the condition is that it does not discriminate in age. Thus, it can make even children its target. But, it goes without saying that it is the aged demographic that is at a higher risk. Symptoms often include lumps, loass of appetite and tiredness.

As both market players as well as governments hurry to remedy the issue, the market is set to witness a steady CAGR (Compound Annual Growth Rate). It will improve the market worth and also improve creation of new opportunities.

Some of the most potent factors driving the growth of the Diffuse Large B-Cell Lymphoma Market are spelled out below:

  • The geriatric population is seeing a massive rise in the age group. It is predicted that by 2050, the number of people belonging to the age group of 65 and above will rise at a great pace bringing the ration of aged population to overall population as 1:6. The situation will be more pronounced in North America and Europe where the ratio will be 1:4. It might be pertinent to note here that in 2018, history was made when for the first time the number of people aged 65 and over surpassed the number of people aged 5 and below.
  • There is continuous research going into this cancer. Already in 2017, it was found that a rare sub-type could use pembrolizumab, a PD-1 inhibitor. 18 participants became a part of the study and proved its efficacy.

Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL) develop from B cells that are abnormal, larger sized cells which are different from healthy, normal B cells. These abnormal cells spread out diffusely all over the tumor, wiping out the lymph node’s normal structure. 

More than 4,800 people in the U.K. are diagnosed with diffuse large B-cell lymphoma every year, according to the U.K. Lymphoma Association. The disease can occur at any age, affecting children as well. However, the aged population is at a higher risk of developing diffuse large B-cell lymphoma. Several patients initially notice painless lumps, usually in their neck, groin, or armpit. Apart from this, loss of appetite, itching, and fatigue are also some other common symptoms.

The continuous development of novel treatments and drugs for treating diffuse large B-cell lymphoma via research and development is assisting the growth of the global diffuse large B-Cell lymphoma market. For instance, in May 2017, it was announced that a rare sub-type of DLBCL, primary mediastinal B-cell lymphoma, can be treated through the use of pembrolizumab, a PD-1 inhibitor. An evaluation of 18 participants with diffuse large B-cell lymphoma under KEYNOTE 013 revealed the safety and efficacy of pembrolizumab.

Diffuse Large B-Cell Lymphoma Market: Overview 

With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the market for DLBCL market is witnessing strong growth across the world. Analysts expect the trend to remain so over the next few years, owing to the increasing number of elderly people, the most prone to DLBCL segment of the overall population. 

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non hodgkin lymphoma (NHL) and is the main reason behind more than 30% of the newly diagnosed cancer cases in the U.S. alone. The prevalence of this disease is increasing at an alarming rate, which is likely to fuel the demand for DLBCL treatments substantially in the near future, leading to a considerable diffuse large B-Cell lymphoma market growth. 

This research report offers a detailed evaluation of the global diffuse large B-Cell lymphoma market on the basis of its current and historical performance. The prominent trends, growth drivers, challenges, opportunities, and the future prospects of this market have also been examined thoroughly while conducting this study. The main objective of this study is to assist the market participants in gaining a clear and deep insight into this market. 

Diffuse Large B-Cell Lymphoma Market: Trends and Opportunities 

The increasing incidence of DLBCL has fueled the demand for efficient therapies for its treatment across the world. With the ever-rising global geriatric population, the scenario is likely to remain more or less similar over the forthcoming years. In addition, the presence of a robust last stage pipeline of drugs ready for clinical trials and the increasing expenditure on healthcare are expected to boost this market tremendously in the years to come. 

At present, the most efficient treatment for DLBCL available across the world is combination therapy that includes chemotherapy and monoclonal antibody-based drug Rituxan (rituximab). However, the development of other drugs is also taking place at a swift pace, with many of them being in various late-stage clinical trials. Alisertib (MLN8237), Bortezomib (Velcade), Brentuximab vedotin (Adcetris), Everolimus (Afinitor), Lenalidomide (Revlimid), Panobinostat, and Vorinostat (Zolinza) are some of the key pipelined projects, approval of which will gain advantages for this market in the forthcoming years. 

Diffuse Large B-Cell Lymphoma Market: Geographical Analysis 

North America, followed by Europe, has surfaced as the leading contributor to the global diffuse large B-Cell lymphoma market, thanks to the high prevalence of DLBCL, rising awareness level of people, and their increased disposable income. However, Asia Pacific is likely to emerge as the most promising regional market in the coming years. The strengthening economy and the improving healthcare infrastructure in this region are expected to act as the key driving force behind the growth of the Asia Pacific diffuse large B-Cell lymphoma market. 

Diffuse Large B-Cell Lymphoma Market: Companies Mentioned in the Report 

Some of the major players operating in diffuse large B-Cell lymphoma market are Amgen, Inc., AstraZeneca plc, Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Gilead Sciences, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG and Sanofi.

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.